In the January 1st issue of G&D, Drs. Thomas Mullen and William Marzluff (UNC Chapel Hill) lend new insight into the degradation of mammalian histone mRNA.

Drugs that treat depression, schizophrenia and other psychotic conditions and that target a particular protein on brain cells might not be triggering the most appropriate response in those cells, new research suggests.